Login Register
icon_bulk_orderBulk order Acrobiosystems for English
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > CD38

CD38

Brief Information

Name:Lymphocyte differentiation antigen CD38
Target Synonym:EC:3.2.2.6,EC:2.4.99.20,2-Phospho-Cyclic-ADP-Ribose Transferase,Cyclic ADP-Ribose Hydrolase 1,2-Phospho-ADP-Ribosyl Cyclase,NAD(+) Nucleosidase,CD38 Antigen (P45),2-Phospho-ADP-Ribosyl Cyclase/2-Phospho-Cyclic-ADP-Ribose Transferase,Ecto-Nicotinamide Adenine Dinucleotide Glycohydrolase,ADP-Ribosyl Cyclase/Cyclic ADP-Ribose Hydrolase 1,Cluster Of Differentiation 38,CD38 Antigen,EC 2.4.99.20,EC 3.2.2.6,ADPRC1,T10,2 -phospho-ADP-ribosyl cyclase,ADPRC 1,cADPr hydrolase 1,ADP-ribosyl cyclase 1,2 -pho
Number of Launched Drugs:3
Number of Drugs in Clinical Trials:18
Lastest Research Phase:Approved

Product ListCompare or Buy

Part of Bioactivity data

CD8-H5224-SPR
Human_FcRn_Heterodimer_Protein_SPR

Anti-CD38 mAb (Human IgG1) captured on CM5 chip via anti-human IgG Fc antibodies surface, can bind Human CD38, His Tag (Cat. No. CD8-H5224) with an affinity constant of 4.98 nM as determined in a SPR assay (Biacore T200) (Routinely tested).

CD8-HF255-ELISA
FITC-Labeled Human CD38, Fc TagFITC-Labeled Human CD38, Fc Tag (Cat. No. CD8-HF255) ELISA bioactivity

Immobilized Anti-CD38 Antibody (Daratumumab), Human IgG1 at 2 μg/mL (100 μL/well) can bind FITC-Labeled Human CD38, Fc Tag (Cat. No. CD8-HF255) with a linear range of 0.078-0.625 μg/mL (QC tested).

Customer Reviews

Synonym Name

CD38,T10,cADPr hydrolase 1

Background

CD antigen CD38 is also known as ADP-ribosyl cyclase 1, which belongs to the ADP-ribosyl cyclase family. CD38 is expressed at high levels in pancreas, liver, kidney, brain, testis, ovary, placenta, malignant lymphoma and neuroblastoma. CD38 is a multifunctional ectoenzyme that catalyzes the synthesis and hydrolysis of cyclic ADP-ribose (cADPR) from NAD+ to ADP-ribose. These reaction products are essential for the regulation of intracellular Ca2+. The loss of CD38 function is associated with impaired immune responses, metabolic disturbances, and behavioral modifications. The CD38 protein is a marker of cell activation. It has been connected to HIV infection, leukemias, myelomas, solid tumors, type II diabetes mellitus and bone metabolism. CD38 has been used as a prognostic marker in leukemia.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Daratumumab/Hyaluronidase-fihj Approved Janssen Global Services Llc Darzalex Faspro, Darzquro Japan Amyloidosis Janssen Pharmaceutical Kk 2020-05-01 Multiple Myeloma; Amyloidosis Details
Daratumumab JNJ-54767414 Approved Janssen Global Services Llc Darzalex, 兆珂, 兆珂速 Mainland China Multiple Myeloma Janssen-Cilag International Nv 2015-11-16 Urologic Neoplasms; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Extranodal NK-T-Cell; Prostatic Neoplasms; Lupus Erythematosus, Systemic; Neuromyelitis Optica; Amyloidosis; Colorectal Neoplasms; Alzheimer Disease; Urinary Bladder Neoplasms; Lymphoma, Non-Hodgkin; Lymphoma; Leukemia, Myeloid, Acute; Leukemia, Monocytic, Acute; Waldenstrom Macroglobulinemia; Large intestine neoplasm; Hypersensitivity; POEMS Syndrome; Hodgkin Disease; Rejection of renal transplantation; Leukemia, Myeloid; Lymphoma, B-Cell; Bone Marrow Neoplasms; Kidney Neoplasms; Genital Neoplasms, Male; Paraproteinemias; Carcinoma, Renal Cell; Purpura, Thrombocytopenic, Idiopathic; Smoldering Multiple Myeloma; Neoplasms; Myelodysplastic Syndromes; Glioblastoma; Lymphoma, Large B-Cell, Diffuse; Immunoglobulin Light-chain Amyloidosis; Multiple Myeloma; Rejection of organ transplantation Details
Isatuximab SAR-650984 Approved Immunogen Inc Sarclisa Japan Multiple Myeloma Sanofi 2020-03-02 Bone Marrow Neoplasms; Paraproteinemias; Smoldering Multiple Myeloma; Carcinoma, Transitional Cell; Hodgkin Disease; Immunoglobulin Light-chain Amyloidosis; Multiple Myeloma; Urinary Bladder Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Anemia, Hemolytic, Autoimmune; Colorectal Neoplasms; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Lymphoma Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
XmAb-968 XmAb968 Phase 1 Clinical Xencor Inc Hematologic Neoplasms; Leukemia, Promyelocytic, Acute Details
Anti CD38 chimeric antigen receptor T-cell therapy (Sorrento Therapeutics) Phase 1 Clinical Celularity, Sorrento Therapeutics Multiple Myeloma Details
211At-OKT10-B10 Phase 1 Clinical Fred Hutchinson Cancer Research Center Multiple Myeloma Details
Anti-BCMA anti-CD38 bispecific chimeric antigen receptor T cell therapy (Shengyan Pharmaceutical Technology) Phase 1 Clinical Wuhan Union Hospital, Shengyan Pharmaceutical Technology Multiple Myeloma Details
GBR-1342 GBR-1342; ISB-1342 Phase 1 Clinical Glenmark Pharmaceuticals Ltd Multiple Myeloma Details
89Zr-DFO-daratumumab Phase 2 Clinical Memorial Sloan Kettering Cancer Center Details
64Cu-DOTA-daratumumab Phase 1 Clinical City Of Hope National Medical Center Multiple Myeloma Details
CART-38 CART-38 The First Affiliated Hospital Of Soochow University Details
TAK-169 TAK-169 Molecular Templates Details
AMG-424 AMG-424 Amgen Inc, Xencor Details
Recombinant human anti-CD38 momoclonal antibody(Sumgen) SG-301; SG301 Phase 1 Clinical Hangzhou Sumgen Biotechnology Co Ltd Hematologic Neoplasms Details
Y-150(Wuhan Yzy Biopharma/CSPC Pharmaceutical) Y-150; Y150 Phase 1 Clinical Wuhan Yzy Biopharma Co Ltd, CSPC Pharmaceutical Group Ltd Multiple Myeloma Details
GEN-3014 GEN-3014 Genmab Details
Modakafusp alfa TEV-48573; TAK-573 Phase 2 Clinical Takeda Pharmaceutical Co Ltd Neoplasms; Multiple Myeloma; Melanoma Details
CART-38(University of Pennsylvania) CART-38 Phase 1 Clinical University Of Pennsylvania Multiple Myeloma; Leukemia, Myeloid, Acute Details
ISB-1442 ISB 1442; ISB-1442 Phase 2 Clinical Ichnos Sciences Sa Multiple Myeloma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute Details
Mezagitamab TAK-079 Phase 2 Clinical Takeda Purpura, Thrombocytopenic, Idiopathic; Myasthenia Gravis; Hematologic Neoplasms; Autoimmune Diseases; Kidney Diseases; Multiple Myeloma; Lupus Erythematosus, Systemic Details
CID-103 CID-103; TSK011010 Phase 1 Clinical Tusk Therapeutics Ltd Multiple Myeloma Details
SAR-442257 SAR-442257 Phase 1 Clinical Sanofi Neoplasms Details
CM-313(Connaught Biomedical Technology) CM-313 Phase 2 Clinical Keymed Biosciences Co Ltd Hematologic Neoplasms; Multiple Myeloma; Lupus Erythematosus, Systemic; Lymphoma Details
4SCAR-T cell therapy (Shenzhen Geno-Immune Medical Institute) 4SCAR-T Phase 2 Clinical Shenzhen Geno-Immune Medical Institute Hematologic Neoplasms; Autoimmune Diseases Details
STI-6129 STI-6129; LNDS-1001 Phase 2 Clinical Sorrento Therapeutics Immunoglobulin Light-chain Amyloidosis; Multiple Myeloma Details
Felzartamab TJ-202; MOR-202; MOR-03087 Phase 3 Clinical Morphosys Ag Glomerulonephritis, IGA; Glomerulonephritis, Membranous; Multiple Myeloma; Rejection of organ transplantation; Lupus Erythematosus, Systemic; Glomerulonephritis Details
SG-2501 SG-2501 Phase 1 Clinical Hangzhou Sumgen Biotechnology Co Ltd Hematologic Neoplasms; Lymphoma Details
TNB-738 TNB-738 Phase 1 Clinical Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America: +1 800-810-0816 (Toll Free)
Asia & Pacific: +86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message